Navigation Links
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
Date:6/11/2008

Quark will lead a lecture and present a poster on proprietary siRNA

targeting and delivery approaches

FREMONT, Calif., June 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced it will participate in the Cambridge Healthcare Institute's 9th Annual Beyond Genome Conference on June 8-11, 2008 at The Fairmont Hotel, San Francisco, CA.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals will be presenting a lecture, "Temporary Inhibition of p53 of siRNA for Prevention of Acute Renal Failure: From Concept to Clinical Trials," at 1:50 PM (PT) on June 11, 2008.

Dr. Feinstein's lecture will discuss AKIi-5 and Quark's proprietary concept of temporarily inhibiting p53 as a systemic therapy to prevent the development of acute kidney injury (AKI) in response to ischemia-reperfusion stress. Following a successful preclinical program focused on safety, AKIi-5 is currently in Phase I clinical trials and represents the first ever systemic dosing of an siRNA in humans.

Dr. Swetlana Boldin-Adamsky, Project Director of Quark, will give a poster presentation, "Non-invasive Aerosol siRNA Delivery for the Treatment of Lung Tumors." The poster will discuss direct delivery of siRNA to the respiratory system by inhalation, a potential delivery method for various disorders, including lung cancer. Remarkably, the anti-cancer siRNA target utilized in these studies was discovered using Quark's proprietary BiFAR functional gene discovery platform. Targeting this gene for cancer treatment is covered by Quark's intellectual property.

Dr. Feinstein stated, "We are excited to participate in this year's Beyond Genome conference. We have successfully administered the first siRNA drug candidate systemically in humans with the initiation of our AKIi-5 Phase I clinical trial. This accomplishment and the inhalation-based delivery of siRNA to the respiratory system demonstrate the unique strengths of our siRNA program."

For more information on the conference please visit: http://www.beyondgenome.com/

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA locally and systemically to organs including the eye, ear, kidney, lung, spinal cord and bone marrow.

Quark's lead product, PF-4523655 (RTP801i-14), completing Phase I/IIa clinical trials, is a synthetic, chemically modified, siRNA molecule to temporarily inhibit the expression of Quark's proprietary target gene RTP801. PF-4523655 is licensed to Pfizer on an exclusive worldwide basis. Quark expects its partner, Pfizer, to continue to progress PF-4523655 through Phase II clinical trials for the treatment of AMD and diabetic macular edema (DME). In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery. Based on publicly available information, Quark believes this was the first siRNA delivered systemically in a human clinical trial. The Company has licenses for AtuRNAi(TM) technology from Silence Therapeutics and additional RNAi intellectual property from Alnylam

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com

Quark Pharmaceuticals, Inc. The Ruth Group

Juliana Friedmann Stephanie Carrington/Sara Ephraim (investors)

+972 89 30 5111 (646) 536-7017 / 7004

jfriedman@quarkpharma.com scarrington@theruthgroup.com

sephraim@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... Two Kalamazoo entrepreneurs ... called fulvic acid that farms, greenhouses and hydroponics operations use to increase yields ... the fastest growing segments of customers using this high grade fulvic acid extracted ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... , VTI, Vertebral Technologies, Inc., announces the successful outcome of the first ... September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product ...
(Date:1/12/2017)... ... ... Huffman Engineering, Inc. , a leader in control systems integration, today announced ... as a chemical engineer. In his new role, Beck will use his extensive ... manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, Beck served for nine ...
(Date:1/12/2017)... Conn. , Jan. 12, 2017   ... company and maker of Flublok Influenza Vaccine ... Zika vaccine candidate had good safety results and ... in preclinical studies. The product is expected to ... few months.  In addition, the Institute of Technology ...
Breaking Biology Technology:
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral ... which grew to over 40 granted and pending patents. ... , , The Company,s ... " System, Device, and Method Estimating Force Applied to a Touch ... forego costly hardware components needed to estimate the force and pressure applied ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
Breaking Biology News(10 mins):